• There is a negative effect of short-term administration of the cox2 inhibitor parecoxib on fracture healing.
• There is a negative effect of short-term administration of the cox2 inhibitor parecoxib on fracture healing.
• There is a negative effect of short-term administration of the cox2 inhibitor parecoxib and the conventional NSAID indomethacin on the earlier fracture healing process.
• There is a negative effect of short-term administration of the cox2 inhibitor parecoxib and the conventional NSAID indomethacin on tendon healing.
• There is a negative effect of short-term administration of the cox2 inhibitor parecoxib and the conventional NSAID indomethacin on tendontobone healing.
Conclusions
Cox inhibitors, both conventional NSAIDs and the specific cox2 inhibitors, have commonly been used in musculoskel etal trauma and orthopedic surgery to reduce inflammatory responses and pain. These drugs are demonstrated to be effi cient in the treatment of postoperative pain related to orthope dic surgery 17 . However, concerns in using cox inhibitors in orthopedic fracture treatment have been raised due to their possible nega tive effect on fracture healing 811 , and similar concerns have also been expressed regarding soft tissue healing 12, 13 .
The present thesis was prepared on the basis of the continu ing discussion in the literature to elucidate the effects of cox inhibitors on fracture healing, tendon healing and tendonto bone healing.
Introduction
and capillaries grow into the gap. Collagen synthesis may begin as early as on the third day and continues over the next 5 to 6 weeks. In the following remodeling phase, consolidation of the tissue from cellular to fibrous develops and at last matu ration of the fibrous tissue to a more scarlike tendon tissue occurs. Collagen fibers near the tendon ends begin to align along the long axis of the tendon, and collagen organization and crosslinking continue over the course of a year. However, after 6 months, there are usually only minimal histological dif ferences between repair tissue and normal tissue 19, 20 .
Tendon-to-bone
Tendons are attached to bone through either fibrocartilagi nous or fibrous insertions. In fibrocartilaginous insertions, typically seen where tendons attach to epiphyses, a charac teristic 4layered architecture is seen, consisting of tendon, nonmineralized fibrocartilage, mineralized fibrocartilage and bone 21, 22 . Fibrous insertions characteristically occur where tendons and ligaments are attached to diaphyseal bone either as a periosteal insertion where the collagen fibers penetrate the bone indirectly via the periosteum, or as a bony insertion where they attach directly to the bone without showing fibro cartilage layers 23 . When healing occurs between tendon and bone inside a bone tunnel, a fibrous insertion develops. Ini tially, a fibrous layer of scar tissue separates tendon and bone 24 and inflammatory cells are also present 25 . Later, collagen fibers from the cancellous bone protrude through this fibrous tissue directly into the tendon in the presence of predomi nantly fibroblastic cells and less inflammatory cells 24, 25 . In a dog model there is continuity between the collagen fibers of the tendon and the surrounding trabecular bone after 26 weeks 24 , indicating that a complete healing has occurred.
In contrast, in another study in rats, a tendon was mechani cally healed in a bone tunnel after 6 weeks 26 . When testing, the specimens ruptured at the muscletendon junction rather than the healing tendontobone junction, maybe due to an intact suture supporting the reattachment during testing and not the healing alone. Most likely more time is needed before solid healing is also achieved in rats, but the time aspect remains uncertain.
Prostaglandin and cyclooxygenase
Prostaglandin (PG) was first identified by von Eular in 1936 27 . Piper and Vane asserted in 1971 that PGs was released from different tissues after stimulation of a PG biosynthesis 28 .
In the acute inflammation cascade the synthesis of PGs begins with release of arachidonate from membrane phos pholipids. Cyclooxygenase (cox), previously named prosta glandin endoperoxide synthase (PGHS), is the key enzyme required for the conversion of arachidonic acid to prostaglan din 29 . Other eicosanoids, like thromboxane, are also synthe sized by cox, and a total number of more than 100 related substances derived from arachidonic acid are recognized 30 . Three cox isoforms have been identified, cox1 31 , cox2 32 and cox3 33 . The cox3 isoform is detected in the central ner vous system and is sensitive to inhibition by acetaminophen/ paracetamol; the role of the cox3 is far from elucidated 30 . The cox1 enzyme is produced constitutively in nearly all tis sues and is mainly responsible for the biosynthesis of PGs involved in homeostatic regulation. Cox2 is inducible and primarily involved in producing PGs in response to a wide spectrum of environmental insults and internal stimuli; i.e. in an acute inflammation 34 .
After a fracture, the release of prostaglandins increase 35 . Dead cells in the area results in an aseptic inflammatory response, and without this inflammation the bone resorp tion and formation necessary for healing cannot occur ade quately 36 . PGs have a direct effect on bone resorption through increased osteoclastic activity 3741 . Furthermore, PGs increase the replication and differentiation of the osteoblasts, resulting in enhanced bone formation 38, 41 . Thus, PGs are partly respon sible for ensuring the balance between bone resorption and bone formation 34, 42, 43 .
It is demonstrated that cox2 plays a critical role in bone resorption 44 , and induction of cox2 in osteoblasts is reported to be essential to the acute stress response in a bone remodel ing system 45 . Furthermore, cox2 is demonstrated to be spe cifically essential for fracture healing 46 and required for both intramembranous and endochondral bone formation 47 . The inflammation is present in the early phase after fracture, and the cox2 mRNA level shows peak expression during the first 2 weeks and a return to basal levels by 3 weeks.
Similarly, it is demonstrated that cox2 regulates early stages of myofiber growth during muscle regeneration 48 , and that cox2 is important in the muscle healing process 49 .
Cox inhibitors
Cox inhibitors are used in the treatment of inflammation and pain. Conventional cox inhibitors, the non steroid anti inflam matory drugs (NSAIDs), inhibit both the cox1 and cox2 enzymes. The newer, selective cox2 inhibitors mainly target the cox2 enzyme.
Vane demonstrated in 1971 that the therapeutic effects of aspirin and indomethacin were due to inhibition of the syn thesis of prostaglandins 50 . Other NSAIDs were developed, including naproxen, ibuprofen, piroxicam, diclofenac, ketoro lac and others. After the discovery of the cox2 enzyme 32 , and the fact that cox2 was inducible 51 , the individual varia tions of activity against cox1 and cox2 between the different NSAIDs were elucidated 52, 53 . Two selective cox2 inhibi tors were introduced in 1999, celecoxib and rofecoxib, they are potent inhibitors of cox2 and weaker inhibitors of cox1 30 . Other cox2 inhibitors have later been developed, such as valdecoxib, parecoxib, etoricoxib and others.
Cox inhibitors show a wide range of side effects, with varia tions between conventional cox inhibitors and cox2 inhibitors, and also between the different conventional cox inhibitors and the different cox2 inhibitors. This variation is probably due to the cox inhibitors variable potency against cox1 and cox2. It has been demonstrated that piroxicam and indomethacin show high gastrointestinal toxicity 54 , and these drugs have a much higher potency against cox1 than cox2 55 .
Fewer serious gastrointestinal adverse events with rofe coxib compared to naproxen were reported 56 . Furthermore, the same study demonstrated that the incidence of myocardial infarctions was higher in patients who were administered rofe coxib, leading to the withdrawal of rofecoxib from the market.
Cannon et al. demonstrated, however, that the rate of throm botic cardiovascular events in patients with arthritis and treated with etoricoxib was similar to those in patients on diclofenac, when considering patients after longterm use of these drugs 57 . Warner and Mitchell also guard against the increasingly prevalent idea that conventional cox inhibitors have inherently lower cardiovascular risks than the specific cox2 inhibitors 58 .
Use of cox inhibitors in orthopedic surgery and trauma
Cox inhibitors have been demonstrated to be efficient in the treatment of postoperative pain related to orthopedic surgery 17 , and are widely in use to reduce opioid analgesia. In a review article the authors conclude that opioid consumption in all included trials was reduced on average by 35 % with cox2 inhibitors 59 . However, it was not possible to demonstrate any definite clinically beneficial effect with reduced opioid related adverse events like nausea.
Cox2 inhibitors are advantageous in relation to surgery as they do not impair the platelet activation and aggregation which is mediated by cox1 through the generation of throm boxane A 2 60 . Therefore they are safer concerning periopera tive bleedings 6165 . Cox2 inhibitors are at least as effective against postoperative pain as the conventional cox inhibitors 6668 , and should probably be the drug of choice when cox inhibitors are indicated.
Recently 21 peerreviewed articles and abstracts concerning the perioperative use of NSAIDs and cox2 inhibitors were retracted after having been identified as fraudulent 6972 . These retractions also compromise every systematic review, meta analysis and editorial that have included these fabricated data, and among other conclusions following these retractions, it was concluded that there is no longer evidence supporting the preemptive effect of NSAIDs and cox2 inhibitors when administered before surgery 73 .
Due to this, the entire area of perioperative pain manage ment should be reassessed.
Effects of cox inhibitors on tissue healing Cox inhibitors effects on fracture healing
It is well documented in experimental studies that cox inhibi tors have a negative effect on bone metabolism and impair fracture healing, both for conventional cox inhibitors like indo methacin 7480 , ibuprofen 8183 , naproxen 84 , ketorolac 8587 and diclofenac 88 , but also for newer specific cox2 inhibitors like celecoxib 46,89,90 , rofecoxib 46,84 , etodolac 91 , valdecoxib 92 and parecoxib 85 . The cox2 enzyme is critically involved in bone repair and required for both intramembranous and endo chondral bone formation 47 , the cox2 function is specifically essential for fracture healing 46 . This indicates that inhibition of the cox2 enzyme is responsible for the impaired healing.
Even shortterm administration of cox inhibitors have a negative effect on the healing process 88, 89, 93 indicating that the initial period after a fracture is important. However, the negative effect seems to be reversible after shortterm admin istration 92, 93 .
Clinical evidence of the effects on bone healing is sparse. In a retrospective study on femoral shaft fractures a marked asso ciation between nonunion and the use of NSAIDs after injury was noted 94 . Delayed healing was also observed in patients administered NSAIDs and whose fractures had united.
A good clinical trial on this subject is a study published by Burd 95 , which observed a patient population randomly allo cated into groups of indomethacin treatment, radiation or no treatment to evaluate heterotopic ossification after surgical treatment of acetabular fracture 96 . These patients had con comitant long bone fractures distributed equally into the three groups, and there was a significant increase of nonunion in patients who received indomethacin compared to those who did not receive indomethacin. There were no nonunions in the acetabular fractures, however, indicating that fractures known to be vulnerable to nonunion or delayed union are exposed when administered cox inhibitors, but not fractures with fewer healing problems in mainly trabecular bone. This is further illustrated by two studies published showing no effect of cox inhibitors on fractures of the distal radius (Colles' fracture) 97, 98 . Nonunions following distal fractures of the radius are extremely rare, and only a few cases have been reported in the literature 99 .
Cox inhibitors effects on tendon healing
The effects of cox inhibitors on tendon healing are less studied than fracture healing. It has been demonstrated that ibuprofen produced a deleterious effect on tendon rupture strength and impaired the healing process 100 . In the healing process, tendon cells migrate to the injury site, proliferate and synthesize col lagen. In an experimental study, celecoxib inhibited both the tendon cell migration and proliferation 101 . It has also been demonstrated that indomethacin might have a negative effect on tendon healing in the early proliferative phase, but might be beneficial in the remodeling phase 102 . This is in accordance with the findings in Virchenko's study, where parecoxib had a negative effect in the early phase of tendon healing, but during remodeling inflammation appeared to have a negative influ ence 103 . This is probably the reason why indomethacin and celecoxib was reported to increase the failure stress in a heal ing tendon 104 . In that study the cox inhibitors were adminis tered until termination after 14 days. This is probably far into the remodeling phase in rats, when cox inhibitors may have a positive influence on healing. It is still unclear, however, how long these healing processes take in human compared to rat, but Virchenko suggests that a week in rats corresponds to a month in humans 103 .
Cox inhibitors effects on tendon-to-bone healing
To achieve normal tendontobone healing, bone ingrowth and mineralization are required 24 . To our knowledge, only 2 experimental studies on cox inhibitors' effects on tendon tobone healing have been previously published. Cohen's study demonstrated that indomethacin and celecoxib impaired rotator cuff tendontobone healing 105 , confirmed with both mechanical testing and histological analysis. The cox inhibi tors appeared to inhibit the formation and maturation of col lagen at the tendon attachment site. In Ferry's study they also demonstrated a detrimental effect on the healing strength at the patellar tendon insertion, when celecoxib, valdecoxib and piroxicam were administered; no effect was seen with ibupro fen and naproxen. A detrimental effect on collagen production was seen with celecoxib, valdecoxib, piroxicam and naproxen, but not with ibuprofen 106 . They suggested that the different absorption and metabolism between the drugs and the uncer tainties of oral drug administration could explain the different inhibition effects between the conventional cox inhibitors.
Cox inhibitors effects on heterotopic ossification
Heterotopic ossification (HO), also named ectopic bone for mation, is a common complication following implant surgery, i.e. hip replacement surgery 107 . The pathogenesis of HO is unclear, but trauma to the soft tissue appears to induce the process. The process is similar to that observed during fracture healing with an initial acute inflammation 108 .
Cox inhibitors have been widely used to prevent HO. Sev eral review articles have been published during recent years confirming preventive effects 109111 , including a Cochrane review 112 . The effect is best documented in total hip replace ments 4,112115 , but cox inhibitors are also effective in prevent ing HO in acetabular fractures 96 and after spinal injuries 116 . Indomethacin has been the drug of choice, but other conven tional cox inhibitors have been shown to be effective as well 114, 115, 117, 118 .
During the last years, the specific cox2 inhibitors have also proved to be as effective as conventional cox inhibitors 119121 . And indeed, findings do indicate that the formation of HO is mainly mediated by cox2 122 .
Traditionally, cox inhibitors have been administered for a period of 4-6 weeks postoperatively in prevention of HO, but shortterm administration for 2-10 days also seems to be effective 118, 123, 124 .
Cox inhibitors effects on spinal fusion
Indomethacin has been shown to inhibit posterior spinal fusions in the rat 125 and the rabbit 87 . Celecoxib delayed allograft healing and incorporation in femoral shaft fractures in mice 126 . In a retrospective clinical study published on spinal fusion, a higher incidence of nonunion was found in patients receiving ketorolac, and an even higher incidence if they also smoked cigarettes 127 . Corresponding findings were observed in another study, but here the patients used cox inhibitors over a longer period 128 . In contrast, ketorolac did not increase the incidence of nonunions in adolescents 129 . However, the inci dence of nonunions in adolescents was as low as 2.5%, indi cating a substantial healing potential in young patients.
Cox inhibitors effects on implant incorporation
Several studies have demonstrated impaired bone ingrowth into porous implants 130132 , and it is also demonstrated that cox2 activity is essential for the osseointegration in a titanium implant 133 . The detrimental effect of perioperatively admin istered indomethacin on bone ingrowth was transient in yet another study 134 , but the model was unloaded. In a clinical setting, restricted weightbearing might be prudent.
It is suggested that the most important cause of implant loosening is osteolysis due to an inflammatory reaction to par ticulate wear debris, in which particles of polyethylene, metal, and bone cement debris are phagocytosed by macrophages. This process is shown to be cox2 dependent, and cox2 con tributes to accelerated bone loss in wear debrisinduced oste olysis. It is also demonstrated that a cox2 inhibitor inhibited titaniuminduced PGE 2 production and inflammation, and due to these effects, cox2 inhibitors might reduce bone loss in inflammationinduced bone disease 135 . Accordingly, cox inhibitors may have a positive effect on the prevention of implant loosening. However, titanium wear debris will prob ably appear some time after the implantation of an implant. Due to this, administration of cox inhibitors should perhaps be avoided during the first days postoperatively to secure bone ingrowth, but administered after some time to prevent wear debris osteolysis.
In a clinical study, there were no radiographical differences after 6 years in patients administered indomethacin 100 mg daily in 6 weeks to prevent HO after cementless total hip pros thesis 136 . Equivalently, the migration of cementless acetabu lar implants were not different in patients administered with indomethacin 100 mg daily in 2 weeks to prevent HO com pared with patients receiving irradiation or the control group 137 . However, in yet another clinical study on HO prevention after cemented hip arthroplasty, there were significantly more revisions due to aseptic loosening or periprosthetic fractures in patients administered ibuprofen 400 mg 3 times daily in 7 or 21 days compared to the placebo 138 .
Recently it was demonstrated that celecoxib did not affect fixation in total knee replacement after 2 years 139 . However, the prostheses were fixed with bone cement. Due to this, fixa tion of the implants did not depend on bone ingrowth, and the cox2 inhibitor could safely be administered.
Cox inhibitors effects on ligament healing
The literature supports neither a positive nor negative influ ence of cox inhibitors on ligament healing. In one study it was demonstrated that piroxicam increased the early heal ing strength of the medial collateral ligament (mcl) in rats after shortterm administration, but the final strength was not affected 140 . In another study, the shortterm administration of celecoxib impaired the early healing of mcl in rats 141 . Short term administration of a specific cox1 inhibitor (SC560) did not have any influence on healing of the mcl in rats 142 . When comparing shortterm administration of different cox inhibi tors, other analgesics and a placebo, piroxicam was found to increase the healing strength of mcl in rats, but no differ ence in healing strength was found in rats administered with naproxen, rofecoxib, butorphanol (opiate) or acetaminophen 143 . In rabbits, no difference in strength was demonstrated in the healing of mcl after 2 weeks of ibuprofen administration 144 .
It is demonstrated in several studies that early motion improves the healing of the mcl 145147 . Treatment with cox inhibitor after mcl injury could, due to the analgesic effect, improve early motion, and may thereby influence healing. However, it is demonstrated that analgesics in general do not appear to affect ligament healing in rats 143 . Uncertain ties related to oral administration, absorption of the drugs and degree of cox inhibition might explain some of the diversity in experimental findings.
Cox inhibitors effects on muscle healing
Piroxicam might delay muscle regeneration in the early period 148 . It has been demonstrated, using both pharmacological and genetic approaches that the cox2 pathway regulated early stages of myofiber growth during muscle regeneration, and that a cox inhibitor reduced the number of myoblasts 48 . Also, the cox2 pathway plays an important role in muscle healing, and prostaglandins are key mediators of the cox2 pathway 149 .
Other studies suggest a negative effect on myofiber growth with both decreased myonuclear addition and decreased inflammation, and a direct regulation of muscle cell activity by cox2. Cox2 activity is important for myofiber growth in multiple physiological conditions 49 .
Ethical considerations
All four studies in this thesis are experimental studies in rats. Unfortunately, neither in vitro models to study the healing processes, nor human methods to test mechanical properties exist. Thus, animal studies were chosen. All studies were per formed using animal models previously published from our group 150154 , and the number of animals was kept to a mini mum in accordance with the statistical power analysis. Spe cially educated personnel supervised the animals on a daily basis. All experiments conformed to and were consented by the Norwegian Council of Animal Research Code for the Care and Use of Animals for Experimental Purposes.
In pharmaceutical studies one should be aware of the ethical considerations related to connections between scientists and the pharmaceutical industry. There may be a great divergence between the companies' aims and those of science 155 
Methodological considerations

Experimental animals
Rats of the Wistar strain were used. In male rats, there is a quick metabolism of the two cox2 inhibitors rofecoxib and celecoxib 157, 158 . This might also apply to parecoxib, the cox2 inhibitor used in our studies. To ensure a halflife comparable to that in humans, we only used female rats in the studies. Rats have been widely used in orthopedic experimental research, and their anatomy and physiology are well known. The bone remodeling in rats is comparable to that in humans 159 , and tendon healing and tendontobone healing are also assumed to resemble human healing. However, the healing processes seem to be much faster in rats 159 , and 2 weeks is therefore a considerable healing time in rat models 103 . The onset of puberty in female rats is at 5 weeks of age 160 . In rat adult hood, each month is roughly equivalent to 2.5 human years
General discussion
161 . However, these time perspectives do not necessarily rep resent corresponding times in rats and humans regarding the tissue healing processes.
Our animal laboratories are modern with excellent facilities. In all studies the animals were kept in pairs in wiretopped plastic cages with free access to tap water and standard labora tory rodent food (with 1.1% calcium, 0.8 % phosphorus and 1500 IU/kg vitamin D 3 ) in a 12hour light and 12hour dark cycle. The animals were taken care of by educated and pro fessional personnel. In all studies the animals gained weight during the course of the experiments.
Drug administration
For surgery and bone density measurements the animals were anesthetized with a combination of Hypnorm (fluanisone 5 mg/mL, fentanyl citrate 0.1575 mg/mL) and Dormicum (mid azolam 2.5 mg/mL). Temgesic (buprenorphin 0.3mg/mL) 0.01ml/100 g body weight was given subcutaneously as anal gesic. The animals were killed with a phenobarbital overdose.
Parecoxib (Dynastat, Pfizer, Pharmacia Europe EEIG, Kent, Great Britain) is a potent and selective inhibitor of cox2 162, 163 for parenteral use and therefore ideal for administration in animal studies. Parecoxib is also claimed to become the anti inflammatory drug of choice for parenteral treatment of post operative pain in the future 164166 . Indomethacin (Confortid, DumexAlpharma A/S, Copenhagen, Denmark) is primarily a cox1 inhibitor 55 and the best documented conventional cox inhibitor to delay fracture healing 46, 75, 76 . This drug is also avail able for parenteral use, and is thus suitable for animal studies.
The cox inhibitors were administered ip twice daily to ensure the best absorption and sufficient blood concentrations. An even better method to ensure constant plasma concentra tion of the drugs, would be to use implantable minipumps 93 . Parecoxib was administered in a dose of 0.05 mg/100 g body weight in the morning and the evening for 7 days, the first injection immediately before surgery. Indomethacin was administered in a dose of 0.0625 mg/100 g body weight at the same time points. These doses are equivalent to human doses. The halflife of cox2 inhibitors is shown to be 3-5 times higher in male rats compared to humans 157, 158, 167, 168 , whereas the halflife in female rats and humans are compa rable 157,168 . Thus we chose to administer human doses, cor rected for weight, to female rats.
Comparing the effects of indomethacin with parecoxib, however, is associated with some uncertainties due to the rats' different metabolism of different cox inhibitors. Any demon strated difference could be dose related, and not drug related. Plasma concentration measurements may have increased the value of the drug comparisons.
Tibial fracture model
In study I and II the right hindlimb of the rats was fractured using a specially designed fracture forceps 169 . Prior to this, a reaming of the medullary canal was performed using an 18 G cannula (BD venflon Pro 18 GA 1.26 IN (1.3 × 32 mm)). Post fracture, this cannula stabilized the tibia, together with a smaller cannula (Braun Sterican 19 G/1,5 IN (1.20 × 40 mm)) passing through the largest one and advancing down towards the ankle joint. On the innermost level, the stylet of a 22 G spinal cannula (Braun Spinocan 22 G x 3 ½ IN (0.73 × 88 mm)) was inserted. This stylet was kept inside the medullary canal when the tibia was fractured to facilitate the reduction of the fracture during fixation 152 . The rotation was only secured by the press fit effect of the cannulas. Rotational instability was not a problem in this model, neither in these studies nor in previous studies from our group.
Tendon rupture model
In Paper III the Achilles tendon of the right hindlimb was cut, and a 3 mm long segment was removed. The tendon was left unsutured 104 . The plantaris tendon was left intact, but care fully dissected free from the healing Achilles tendon before mechanical testing. Whether maintaining the plantaris tendon leads to more or less weight bearing may be questioned. The plantaris tendon is strong in rats, and can take over some func tion after the Achilles tendon is injured. However, even if the animals are allowed full weight bearing, they generally protect their operated hind limb. Due to this, we believe that keep ing the plantaris tendon intact may result in increased load ing of the operated limb, and tendon loading has been shown to increase PG release, DNA and protein synthesis 102 . This factor might have significance for the healing after treatment with cox inhibitors. In cox inhibitor treated animals this would probably not have the same importance due to the impaired PG production, but in placebo animals increased PG could possi bly increase healing, resulting in larger differences between the groups. The animals in our study were allowed full weight bearing with no immobilization. All tendons healed. No time study was performed to elucidate if the healing tendons would have regained full strength during the later course of healing.
Tendon-to-bone model
In study IV, no previous model in the rat was available, to our knowledge. We therefore developed our own model in a pilot study to confirm the surgical technique and decide the time point of termination. In the pilot study we killed the animals and did the dissections and mechanical testing at three time points; 10, 14 and 18 days. After 14 days we observed satisfac tory healing and the best conditions for soft tissue dissection. This was in accordance with a tendontobone healing study demonstrating that the tendon was attached securely within the bone tunnel after 14 days 25 . Time studies would of course have been of great interest to elucidate if the impaired healing was transient and the healing would be restored in the long term.
Our main aim was to elucidate if the healing was impaired at an early time point as this might have a direct impact on patient mobilization after reconstructions using tendon grafts in bone tunnels. The Achilles tendon was dissected free from the calf muscle proximally and all muscle fibers were removed from the tendon. The tendon was then pulled through a 2 mm drill hole in distal tibia and secured anteriorly to the perios teum with a suture with the ankle joint held in 90 degrees. The animals were allowed full weight on their injured legs, with no immobilization. Therefore, the tendon was put under tension during mobilization. After 14 days the Achilles tendons were meticulously dissected free from the bone. The only remain ing contact between tendon and bone was inside the drill hole. This was probably the most crucial point in the surgical pro cedure. 2 tendons from each group slipped out during the dis section, probably due to improper healing of the tendon in the bone tunnel. These specimens were excluded.
BMD measurements
Lunar PIXIMUS (Lunar, Madison, Wisconsin, USA) is spe cially designed for BMD measurements on small animals using Dual Energy Xray Absorptiometry (DEXA). By using this method, we were able to measure BMD at the fracture site on anesthetized animals at different time points during heal ing. The intramedullary nail had to be included in the mea surements, but its constant value was subtracted from the cal culated BMD values to estimate the real BMD at the fracture site. As the intramedullary nail was included in the measure ments, the real difference in BMD in the fracture callus was probably larger than observed, since the nail represented an equal constant in all groups. To validate this method, we also measured BMD after killing and removal of the nail, and this showed equal results indicating that the DEXA measurement with the nail in place was a reliable method. In Paper I the BMD after treatment with parecoxib at 0.05 mg/100 g body weight did not differ significantly from placebo after 3 weeks (p < 0.06) in contrast with the results from Paper II where animals treated with the same dose of parecoxib, for the same period of time did show difference in BMD values when com pared with the placebo group. However, in both studies, the values were borderline significant values, one just over and the other one just below a pvalue of 0.05. Our first study was possibly underpowered, explaining the difference between the results in the two Papers. Furthermore, we used animals from two different producers and strains in these two studies, this may also have contributed to the small differences in BMD.
Mechanical bone testing
In study I and II a threepoint cantilever bending test was used. The test was originally developed for the rat femoral shaft 170 154 . Fourpoint bending tests or torsional tests are often used for mechanical testing of the soft callus due to concerns related to possible deformation of the soft callus from the fulcrum in threepoint bending. However, in our threepoint bending test, the distal tibia is fixed, and the proximal fragment is bent in an anterior direction, so that the fulcrum is not moving or sagging into the callus. The threepoint bending test gains standardized frac tures and reliable results, and have been used by our group in several previous studies published in peerreviewed journals 150153, 170 . Both the fractured right tibia and the intact left tibia were fractured and the bending moment, total energy, deflec tion and bending stiffness were registered and calculated. The ratios between the right and the left tibia for the four mechani cal properties were calculated.
The bending moment is the ultimate load the bone can with stand before fracture (top point of the gray loaddisplacement curve) multiplied by the moment arm by which the load is applied in the MTS machine. The total energy is the energy absorbed by the bone until fracture (the area under the curve until failure excluded the preloading). Deflection is the ulti mate deformation in the bending of the bone before fracture (the point on the displacement axis corresponding to the fracture point). Stiffness is the ratio of the applied bending moment on the corresponding deflection in the straight, elastic part of the loaddisplacement curve (the black line).
Mechanical tendon testing
In Paper III a stretching test aligned parallel with the tendon was performed. The proximal tendon was spread like a fan and clamped between fine grained sand paper, and the cal caneus was held in a claw 104 . No healing tendons slipped in the clamp during testing, but when testing intact tendons, they slipped out of the clamp before rupturing. Thus, ratios could not be compared like in studies I and II. The tensile strength (stretching force), total energy, deflection and stretching stiff ness were registered.
Tensile strength was the ultimate load the tendon could with stand before rupture. Total energy was the energy absorbed by the tendon until rupture. Deflection was the ultimate stretch ing of the tendon before rupture. Stiffness was the ratio of the applied force on the corresponding deflection in the straight, elastic part of the loaddisplacement curve (black line).
Mechanical tendon-to-bone testing
In Paper IV a pull out test was performed. The calcaneus was held in the same claw as in Paper III, while the tibia was fixed in a custom made metal clamp. This clamp ensured that the drill hole was aligned with the direction of the force applied, and there was no contact between the tendon and the metal clamp. The ultimate pull out strength, total energy, deflection pullout and stiffness were registered.
Pullout strength was the ultimate load that the tendontobone junction could withstand before failure. Total energy was the energy absorbed by the tendontobone interface until failure. Deflection was the ultimate stretching of the tendontobone interface before failure. Stretching stiffness was the ratio of the applied force on the corresponding deflection in the straight, elastic part of the loaddisplacement curve (black line).
Statistical analysis
All the mechanical data were registered in TestStar software (MTS Systems, Corporation Eden Prarie, Minnesota, USA) and calculations were made in SPSS for Macintosh (SPSS Inc., Chicago, Illinois, USA). Statistical significance was set at p < 0.05.
In Paper I, the two groups were compared by an unpaired Students ttest. For the DEXA measurements Bonferroni adjustment for multiple timepoint tests were applied.
In Paper II-IV the three groups were compared using Analysis of Variance (ANOVA). Scheffe's post hoc test 171 was chosen to demonstrate if there was a negative effect of parecoxib and indomethacin on healing to give maximum pro tection against type I errors.
In these studies we demonstrated that cox inhibitors reduced the BMD and impaired the mechanical strength in healing fractures. Tendon healing and tendontobone healing were also impaired.
From our studies, and previous studies published on this topic, there should be no doubt about the cox inhibitors nega tive effect on the healing process. However, there are numer ous uncertainties connected to the degree of significance for tissue healing in humans.
One of the important questions concerning cox inhibitors' effect on tissue healing is whether shortterm administration of these drugs in relation to surgery or injury only temporar ily delay the healing or definitely influence the final outcome.
In study I we demonstrated that parecoxib exerted an inhibi tory effect on the mineralization of fracture callus, but the study suggested that the effect was temporary. The difference between BMD in the two groups was largest after 2 weeks, and after 6 weeks there were no significant differences. In study II we demonstrated similar results; the difference between BMD in animals administered indomethacin and the placebo group was largest after 2 weeks, but there were no significant differ ences after 3 weeks. Comparable results have been demon strated in other studies using radiological analysis 89 or radio logical bone density calculations 88 , even though the duration of drug administration differed in the groups they compared. Fractures in animals administered cox inhibitors for a short time period had better radiological signs of healing compared to animals administered cox inhibitors for a longer period.
Concerning mechanical testing we did not find differences when testing after 6 weeks in study I. However, when testing earlier in the healing period (3 weeks, study II), there was a significantly decreased strength in animals administered both parecoxib and indomethacin compared to the placebo group. This also indicates that when administering cox inhibitors shortterm only, the negative effects are reversible. Corre sponding findings are seen in other studies 89, 92 . Histologi cally, significantly more fibrous tissue and less woven bone formation were found after 4 and 8 weeks, but not after 12 weeks 172 . Initiating cox inhibitor treatment in the later course of fracture healing may also have a negative effect on the heal ing process, but not to the same extent as when treatment is administered around the time of fracture 89 .
Thus, shortterm administration of cox inhibitors delays fracture healing, but the healing process is probably restored when inhibition is removed.
Tendon healing is different from bone healing. In Paper III we demonstrated impaired tendon healing after shortterm administration of parecoxib or indomethacin. It has previously been suggested that cox inhibitors might have a negative effect Results on the proliferative phase of tendon healing, but might have a positive effect in the remodeling phase 102 . Accordingly it is demonstrated that inflammation appears to have a negative influence during remodeling 103 . Long term application of cox inhibitors are reported to increase the failure stress in a healing tendon when administered until trial termination, i.e. during both the proliferative phase and the remodeling phase 104 .
In Paper III the cox inhibitors were administered in the early phase only. Due to this, the proliferation phase was inhibited, and healing was impaired.
Consequently, shortterm cox inhibitor administration delay tendon healing. However, administered in the later phase of healing cox inhibitors might be beneficial.
Tendontobone healing is also different from both frac ture healing and tendon healing. However, like in fractures and tendon injuries, the healing process is initiated with an inflammatory phase. In Paper IV we demonstrated that short term administration of parecoxib and indomethacin impaired tendontobone healing.
In Ferry's study 106 they administered the drugs until ter mination after 2 weeks, and patellar tendontobone healing strength was decreased by the cox2 inhibitors celecoxib and valdecoxib, and also by the conventional NSAID piroxicam, but not by naproxen and ibuprofen. Collagen content at the repair site was decreased for all but ibuprofen. The differences between the cox inhibitors were probably due to inadequate dosages or different metabolism of the drugs 106 . In Cohen's study 105 they administered the drugs for 2 weeks, and demon strated significantly lower failure loads in rotator cuff sutures after 2, 4 and 8 weeks in rats administered celecoxib or indo methacin, when compared to the placebo. The differences persisted at 8 weeks, and in contrast to findings in fracture healing, there was no indication that the impairment of ten dontobone healing was temporary. Thus, regarding tendon tobone healing, shortterm administration impairs healing. It remains unclear whether the negative effects of cox inhibitors on tendontobone healing are transient or persistent.
Another important question is whether inhibition of cox1 or cox2 is responsible for the negative effects on the healing process.
The cox2 enzyme is inducible and involved in producing PGs related to acute inflammations, while the cox1 enzyme is produced constitutively and involved in the homeostatic regula tion 34 . Therefore, one would expect that the inducible cox2 was the enzyme involved in the healing process. In a study using mice genetically deficient for cox1 or cox2 enzyme, it was demonstrated that cox2 is critically involved in bone repair and required for both intramembranous and endochondral bone formation 47 . In another study using these mice, and also rats, administered both conventional cox inhibitors and cox2 inhibi tors, they also demonstrated that cox2 function was specifi cally essential for fracture healing 46 . Several other studies have also demonstrated that cox2 inhibitors impair fracture healing 8992 . Furthermore, cox2 plays an essential role in osseointe gration of implants 133 , and inhibits rotator cuff tendontobone healing in rats 105 . Cox2 activity is also crucial during the early stages of muscle regeneration; muscle regeneration was attenu ated by a cox2 inhibitor but was unaffected by cox1 inhibi tion, and cox2 inhibition resulted in fewer myoblasts 48 . Cox2 also regulates growth of atrophied muscle 49 .
In fracture calluses in rats, cox2 mRNA levels showed peak expression during the first 2 weeks of healing in rats and returned to basal levels by 3 weeks 85 . Accordingly, PGE 2 reached the highest levels 24 hours after fracture and declined to baseline by 35 days 92 . The PGE 2 levels in the callus were reduced when cox inhibitors were administered to the animals 89, 92 . PGE 2 was the first PG shown to influence bone metab olism 39 , and a PGE 2 agonist specifically promoted fracture healing 173 . PGE 2 has been assumed to be the major product of cox2 activity and being the primary mediator of the anabolic activities in skeletal cells 174 . Furthermore, cox2 is induced early in response to muscle injury, and mRNA levels peak 4 days after injury 48 .
In the present thesis, the specific cox2 inhibitor parecoxib showed a more pronounced negative effect on fracture heal ing, tendon healing and tendontobone healing compared to the conventional NSAID indomethacin. This is in accordance with findings reported in the literature in general. Consider ing findings in earlier published studies, we expected to find impaired healing in rats administered indomethacin in human doses adjusted for weight in rats. We hypothesized that even more reduced healing in rats administered parecoxib in human doses would argue for inhibition of cox2 to be the respon sible mechanism. However, due to uncertainties related to the metabolism of different NSAIDs and cox2 inhibitors in rats, we cannot conclude that cox2 inhibition is responsible for the impaired healing. Altogether, however, findings indicate that cox2 is the enzyme responsible for initiating the heal ing process and that inhibition of cox2 is responsible for the impaired healing. Due to this, inhibition of cox2 during the early period after injury or surgery seems to have the most detrimental effects on tissue healing.
Impaired healing on the basis of cox inhibition is probably not due to inhibition of the inflammation alone. Several mech anisms are most likely involved.
PGs are synthesized in the inflammatory process, and are important to initiate bone healing 36 . PGs also play an impor tant role in regulating bone metabolism and preventing an imbalance between bone resorption and bone formation 34, 42, 43 . When a cox2 inhibitor was administered 2 weeks after fracture, a negative effect on healing was still observed 89 . This suggests that cox2 might have additional functions during fracture healing besides inhibiting PGs.
Angionesis is essential for successful fracture healing and endochondral ossification 175, 176 . Angionesis is also shown to be inhibited by cox2 inhibitors 177 , and vascularization of fracture callus in mice genetically deficient for cox2 is reported to be reduced 46 . This might lead to improper deliv ery of osteclasts and osteoblasts to the fracture area.
Corresponding mechanisms are seen after muscle injury where the intramuscular number of inflammatory cells as mac rophages are decreased 48 . Muscle regeneration is impaired when inflammatory cells are depleted and stimulated when they are increased 178 . Macrophages are necessary in the repair process to phagocytose cellular debris and secrete growth fac tors, cytokines and PGs that are implicated in myogenesis 179, 180 . The majority of macrophages in injured muscle are claimed to invade from circulation and are not a result of the proliferation of resident macrophages 181 . Therefore, impaired release of vasodilatory PGs by cox2 inhibition might also lead to improper delivery of inflammatory cells to the injury site, not only in muscle, but in tendon and bone as well.
Bone morphogenetic proteins (BMPs), which are important regulators of bone formation, might also be affected by cox inhibition. In a study using bone marrow stromal cell cultures obtained from mice genetically deficient for cox2, findings suggested that reduced PGE 2 level due to cox2 inhibition interfere with BMP2 signaling events leading to reduced levels of 2 genes necessary for bone formation 47 . Another study demonstrated similar findings where the expression of BMP7 was increased upon PGE 2 treatment 182 . Also con cerning tendon healing, and probably tendontobone heal ing, these mechanisms might be present as BMPs, and may be necessary for normal repair. Other BMPs, like the cartilage derived morphogenic proteins (CDMPs) is demonstrated to improve early tendon healing 183185 , and reduced PGE 2 due to cox inhibition, might interfere with CDMP2 signaling.
It is also shown that mice, genetically deficient for cox2, have elevated plasma levels of both Ca 2+ and PTH consis tent with primary hyperparathyroidism, suggesting that the cox enzymes are regulators of BMD and bone strength 186 . The same study demonstrates lower BMD, decreased bone strength and decreased trabecular volume in mice genetically deficient for cox2. In summary, findings from different studies indicates that fracture healing, tendon healing and tendontobone healing, regulated through the cox2 pathway, involve multiple mecha nisms, not only the inhibition of inflammation.
Altogether, shortterm administration of cox inhibitors impairs the healing process in bone and tendons. Administered in doses equivalent to human doses, the inhibition is more pro nounced with cox2 inhibition than with cox1 inhibition.
Clinical considerations
An important question concerning cox inhibitors and tissue healing in relation to this thesis is the clinical relevance of the findings; results of experimental animal studies cannot be directly extrapolated to the human clinical setting. However, as long as experimental studies demonstrate that cox inhibi tors are potentially deleterious to healing of bone, tendon and tendontobone, these studies should be our guidance and make clinicians aware of the possible deleterious effects on musculoskeletal tissue healing of these drugs.
Aspenberg asserted in an Editorial in 2002 that cox inhibi tors should be avoided after skeletal surgery 8 . Few studies have been published since that would cause one to change this view. However, cox inhibitors could probably be considered for administration after fractures that usually incur few or no healing problems, like distal radial fractures and acetabular fractures. This is in accordance with findings in Burd's study were 29% of patients administered indomethacin had a non union of a long bone fracture, but all acetabular fractures in the same patients healed 95 . Concerning arthroplasties, it has recently been demonstrated that administration of cox inhibi tors to patients after implantation of cemented knee prosthe ses did not affect the outcome after 2 years 139 . It is likely that cox inhibitors can be administered when implanting cemented prostheses, where bone ingrowth into the implant is not required. One should be aware, however, of a possibly ele vated risk of infections. In a prospective randomized study on patients undergoing coronary artery bypass surgery, there was an increased incidence of sternal wound infections in patients administered cox2 inhibitors compared to the placebo 187 . Considered the severity infected arthroplasties in particular, and deep infections in relation to orthopedic surgery in gen eral, it is important to elucidate if cox inhibitors have an effect on wound healing and wound infections.
No prospective randomized clinical trial on long bone frac tures with or without cox inhibitor treatment have been per formed. However, an association between the use of NSAIDs after injury and nonunion in human has been observed for femoral shaft fractures in retrospective studies 94, 95 . This sup ports the findings from a large number of experimental stud ies. It is not unlikely that these findings also apply to all human fractures known to be vulnerable to nonunion and delayed union and other similar bone healing situations. Although the negative effect of shortterm administration of cox inhibitors on fracture healing seems to be transient in the experimental studies, this might not be the case in humans, as the fracture healing potential is much better in rats compared to humans. So, cox inhibitors should be avoided in situations were unim paired healing is essential for the outcome, i.e. fractures with known healing problems, spinal fusions, arthrodesis, osteoto mies and after bone grafting procedures. Moreover, cox inhib itors should probably be avoided in implant surgery where bone ingrowth is essential.
Concerning soft tissue healing in a clinical setting, cox inhibitors are widely used for sports related injuries and after surgery. Lately, however, concerns also have been expressed regarding the treatment of muscle, ligament and tendon inju ries as long as they might be potentially deleterious to tissue healing 12, 13 . Prospective randomized clinical trials have not been performed in terms of tendon or tendontobone healing,. Based on experimental studies, however, cox inhibitors should probably be avoided in the proliferation phase, but might be considered for administration in the later remodeling phase during soft tissue healing in tendons and ligaments. Further more, after procedures requiring tendontobone healing like rotator cuff repairs, tendon reinsertions and cruciate ligament reconstructions cox inhibitors should probably be avoided altogether.
There are still numerous unknown aspects of the use of cox inhibitors. The negative effects on healing of musculoskeletal tissue demonstrated in experimental studies should be thor oughly elucidated in clinical studies before cox inhibitors are administered to these patients.
